Literature DB >> 7028767

Determination of some pyridinium aldoxime compounds by means of ion-pair reversed-phase high-performance liquid chromatography: application in biological material.

H P Benschop, K A Konings, S P Kossen, D A Ligtenstein.   

Abstract

Two reversed-phase high-performance liquid chromatographic systems are presented for the separation and assay of the pyridinium aldoximes benzyl-P2A, HI-6 and obidoxime in aqueous solutions and biological samples. The systems involve a 5-micrometer C18 silica gel stationary phase. The eluent consists of methanol, acetic acid buffer (pH 4.80), a counter ion (per-chlorate or n-octanesulphonate) and a surfactant. The compounds were detected spectrophotometrically at 304 nm. In the concentration range used, linear plots of concentration versus extinction were obtained, both in blood and in water. Detection limits plots of concentration versus extinction were obtained, both in blood and in water. Detection limits, even in blood are satisfactory (0.5-1 microM). Evidence of presented that, at least for HI-6, the addition of counter ions to the system does not lead to the formation of ion pairs to be retained by partition, but rather to a mechanism based on adsorption chromatography.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028767     DOI: 10.1016/s0378-4347(00)80249-2

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Pharmacokinetics and efficacies of obidoxime and atropine in paraoxon poisoning.

Authors:  K Schoene; A König; H Oldiges; M Krügel
Journal:  Arch Toxicol       Date:  1988-04       Impact factor: 5.153

2.  The acetylcholinesterase reactivator HI-6 (1-[[[4-(aminocarbonyl)pyridinio]methoxyl]methyl]- 2-[(hydroxyimino)methyl]-pyridinium dichloride): a comparative study of HI-6 samples from various sources.

Authors:  J G Clement; P A Lockwood; H G Thompson
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

3.  Therapy of organophosphate poisoning: the marmoset as a model for man.

Authors:  H P van Helden; H J van der Wiel; O L Wolthuis
Journal:  Br J Pharmacol       Date:  1983-03       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.